Zinc acexamate (ZAC) is a new drug for the treatment of peptic ulcer. The present study was performed in order to evaluate the clinical efficacy of ZAC in peptic ulcer, using a meta-analysis of all randomized clinical trials performed with this drug. Eighteen studies were reviewed, but only 13 were considered in the final analysis. The total number of patients was 757. Control groups included placebo or H2 receptor antagonist drugs. Healing rate, assessed by endoscopy, was selected as the criterion for evaluating drug efficacy. The meta-analysis was performed using a modified version of the Mantel-Haenszel method. ZAC proved to be better than placebo in the treatment of peptic ulcer (pooled odds ratio: POR = 5.55; 95% confidence interval: 95% CI = 2.20-14.04) and not different from H2 receptor antagonist drugs when compared in patients with gastric (POR = 1.14; 95% CI = 0.47-2.72), duodenal (POR = 0.97; 95% CI = 0.13-7.33) or both ulcer types (POR = 1.10; 95% CI = 0.74-1.64). The present results show that ZAC is an effective drug for the treatment of peptic ulcer.

中文翻译：

---

醋氨酸锌治疗消化性溃疡疗效的Meta分析

Zinc acexamate (ZAC) 是一种治疗消化性溃疡的新药。进行本研究是为了评估 ZAC 在消化性溃疡中的临床疗效，使用该药物进行的所有随机临床试验的荟萃分析。审查了 18 项研究，但最终分析只考虑了 13 项。患者总数为 757。对照组包括安慰剂或 H2 受体拮抗剂药物。选择通过内窥镜评估的愈合率作为评价药物疗效的标准。荟萃分析是使用 Mantel-Haenszel 方法的修改版本进行的。ZAC 被证明在治疗消化性溃疡方面优于安慰剂（合并优势比：POR = 5.55；95% 置信区间：95% CI = 2.20-14。04) 与 H2 受体拮抗剂药物相比，在胃 (POR = 1.14; 95% CI = 0.47-2.72)、十二指肠 (POR = 0.97; 95% CI = 0.13-7.33) 或两种溃疡类型 (POR = 1.10；95% CI = 0.74-1.64)。目前的结果表明ZAC是一种治疗消化性溃疡的有效药物。